Lost password ?
<< Back to Equity Research
SIPHAT
SIPHAT, TO BE AVOIDED UNTIL FURTHER NOTICE
Aug 29 - It is not surprising if our last short paper on Siphat (Sell, Tunisia) was since a long time relatively (7 months) as nothing has changed and the newsflow is still negative. Indeed, the share ...
Executive summary
Conflict of Interest
Pages 36
Language English
Publish on August 29, 2022
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
Mar 19 AM
Gulf Pharmaceutical
A better Q4 lifted our Target Price
Mar 16 PM
Gulf Pharmaceutical
A hit from outside GCC revenues in 2023
Mar 04 PM
Gulf Pharmaceutical
Modest 2023 results despite a better-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ